Henry N Nelson, MD in Melbourne, FL - Urology

Henry N Nelson, MD is a Urology physician based in Melbourne, Florida. Henry N Nelson is licensed to practice in Florida (license number ME36295) and his current practice location is 1130 Hickory St, Melbourne, Florida. He can be reached at his office (for appointments etc.) via phone at (321) 725-4500.

NPI number for Henry N Nelson is 1417931676 and his current mailing address is 200 E Sheridan Rd, Melbourne, Florida. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1417931676.

Contact Information

	Henry N Nelson, MD
	1130 Hickory St, Melbourne, FL 32901-1946
	(321) 725-4500
	(321) 951-3124

Physician's Profile

Full Name	Henry N Nelson
Gender	Male
Speciality	Urology
Location	1130 Hickory St, Melbourne, Florida
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1417931676
Provider Enumeration Date: 12/01/2005
Last Update Date: 07/10/2008

Medical Identifiers

Medical identifiers for Henry N Nelson such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1417931676	NPI	-	NPPES
020009895	Other	FL	RR MEDICARE
039788100	Medicaid	FL

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208800000X	Urology	ME36295 (Florida)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Henry N Nelson is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Henry N Nelson, MD 200 E Sheridan Rd, Melbourne, FL 32901-3142 Ph: (321) 725-4500	Henry N Nelson, MD 1130 Hickory St, Melbourne, FL 32901-1946 Ph: (321) 725-4500

News Archive

MSTF recommends colonoscopy and FIT as first tier screening tests for colorectal cancer

In its latest recommendations, the US Multi-Society Task Force on Colorectal Cancer Screening confirms that people at average risk should be screened beginning at age 50, and recommends colonoscopy and fecal immunochemical testing as the "first tier" screening tests for this group.

New gene therapy approach to treating DMD reduces symptoms, extends life span in mouse model

A gene therapy approach to treating the progressive muscle wasting disorder Duchenne muscular dystrophy (DMD) that does not replace the mutated DMD gene but instead delivers the gene for ITGA7, a protein in skeletal muscle, led to reduced symptoms and significantly extended life span in a mouse model of severe DMD. Over-expression of ITGA7 did not elicit an immune reaction, further supporting its potential as a novel treatment for DMD, according to a new study published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

Physicians to educate Congress on the importance of reducing viral hepatitis

The National Viral Hepatitis Roundtable (NVHR) is hosting a briefing, "The Experts' Perspective: Gaps and Strategies in the Hepatitis Crisis." "Leading hepatitis physicians, one of whom is a Congressman, will be on the hill today to educate Congress on the importance of developing a strategy to reduce the significant morbidity and mortality from end-stage liver disease and liver cancer caused by chronic hepatitis B and chronic hepatitis C in the United States," said Martha Saly, Director of NVHR.

Health Net's MA product portfolio offers budget-friendly health plan choices to beneficiaries for 2010

With the kick-off of the Medicare Annual Election Period (AEP) this week, Health Net, Inc. reminds those eligible for Medicare that Health Net's Medicare Advantage (MA) product portfolio offers a comprehensive range of budget-friendly health plan choices to beneficiaries for 2010.

Experimental Therapeutics, Debiopharm join to develop oral small molecules targeting new class of epigenetic modulators

The Agency for Science, Technology and Research (A*STAR)'s Experimental Therapeutics Centre (ETC), a center of excellence to advance and accelerate drug discovery in Singapore, and Debiopharm Group™ (Debiopharm), the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology as well as companion diagnostics, today announced the signature of an exclusive research collaboration to develop oral small molecules targeting new class of epigenetic modulators.

Urology Doctors in Melbourne, FL

Dr. Robert C Allen Jr., M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 1350 Hickory St, Melbourne, FL 32901 Phone: 321-434-1771 Fax: 321-434-1775
Larry Jackson Landry, MD Urology Medicare: Medicare Enrolled Practice Location: 2200 W Eau Gallie Blvd, Suite 202a, Melbourne, FL 32935 Phone: 321-253-1992 Fax: 321-253-1844
Thomas D Fields, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 1223 Gateway Drive, Melbourne, FL 32901 Phone: 321-725-4500 Fax: 321-768-0039
Matei T Andreoiu, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 8725 N Wickham Rd Ste 202, Melbourne, FL 32940 Phone: 321-434-9528 Fax: 321-434-9529
Dr. Steven O Bossinger, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1350 Hickory St, Melbourne, FL 32901 Phone: 321-434-1771 Fax: 321-434-1775
Emily Fell Kelly, MD Urology Medicare: Medicare Enrolled Practice Location: 1223 Gateway Dr Ste 2a, Melbourne, FL 32901 Phone: 321-361-5567 Fax: 321-951-3124
Dr. Douglas P Sorensen, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 200 Michigan Ave, Melbourne, FL 32901 Phone: 321-724-4400 Fax: 321-724-1139

Henry N Nelson, MD - Urology in Melbourne, FL